Company / R&D Expense
BridgeBio Pharma, Inc. R&D Expense History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$452.0M
FY2025
5-year range
$209.9M / $506.5M
FY2021-FY2025
Trend
-10.8%
vs FY2024
Sector context
#39 of 210
Health Care
What the data says
BridgeBio Pharma, Inc.'s r&d expense of $452M is higher than 81% of companies in the Health Care sector (FY2025). R&D Expense has fluctuated over the past 9 years, ranging from $31M in FY2017 to $506M in FY2024.
Based on SEC 10-K filings.
$452M in FY2025 with a 5-year CAGR of +6.0%. Top quartile in the Health Care sector.
Remained stable around $452M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +4.2%
- 5-Year CAGR
- +6.0%
- 10-Year CAGR
- -
Sector benchmark
Top 19% in Health CareTop 19% of 210This company $452.0M Sector average $644.0M
▼
-29.8% below sector average
Key checks
Key Insights
- 5-year CAGR of +6.0%, indicating consistent growth.
- In FY2025, r&d expense decreased 10.8% year-over-year.
- Ranks #39 out of 210 companies in the Health Care sector.
- Peak r&d expense was recorded in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -4.56 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $452.0M | -10.8% |
| FY2024 | $506.5M | +12.3% |
| FY2023 | $451.0M | +12.9% |
| FY2022 | $399.5M | +90.3% |
| FY2021 | $209.9M | -37.7% |
| FY2020 | $337.0M | +60.5% |
| FY2019 | $209.9M | +49.9% |
| FY2018 | $140.1M | +358.4% |
| FY2017 | $30.6M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026